CN106798252A - A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect - Google Patents
A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect Download PDFInfo
- Publication number
- CN106798252A CN106798252A CN201710042376.2A CN201710042376A CN106798252A CN 106798252 A CN106798252 A CN 106798252A CN 201710042376 A CN201710042376 A CN 201710042376A CN 106798252 A CN106798252 A CN 106798252A
- Authority
- CN
- China
- Prior art keywords
- natto
- prescription
- parts
- oligosaccharide
- reducing blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013557 nattō Nutrition 0.000 title claims abstract description 119
- 230000000694 effects Effects 0.000 title claims abstract description 57
- 210000004369 blood Anatomy 0.000 title claims abstract description 56
- 239000008280 blood Substances 0.000 title claims abstract description 56
- 210000000936 intestine Anatomy 0.000 title claims abstract description 42
- 210000002784 stomach Anatomy 0.000 title claims abstract description 40
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 33
- 150000002632 lipids Chemical class 0.000 title claims abstract description 25
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 49
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 49
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 38
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 38
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 35
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 35
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 35
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 35
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 35
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 35
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 35
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 35
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 35
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 35
- 239000000843 powder Substances 0.000 claims abstract description 33
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 21
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 12
- 241001092040 Crataegus Species 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 6
- 108010073682 nattokinase Proteins 0.000 claims description 5
- 229940086319 nattokinase Drugs 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- -1 pulvis Substances 0.000 claims description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 32
- 235000012000 cholesterol Nutrition 0.000 abstract description 12
- 210000002966 serum Anatomy 0.000 abstract description 12
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 6
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 6
- 230000029087 digestion Effects 0.000 abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000002792 vascular Effects 0.000 abstract description 4
- 239000006041 probiotic Substances 0.000 abstract description 3
- 235000018291 probiotics Nutrition 0.000 abstract description 3
- 230000002079 cooperative effect Effects 0.000 abstract description 2
- 230000007661 gastrointestinal function Effects 0.000 abstract description 2
- 244000005709 gut microbiome Species 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 241000700159 Rattus Species 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 description 12
- 244000068988 Glycine max Species 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 10
- 238000003304 gavage Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 244000046052 Phaseolus vulgaris Species 0.000 description 6
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000003746 solid phase reaction Methods 0.000 description 2
- 238000010671 solid-state reaction Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000011497 sour milk drink Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect, the natto prescription is grouped into by each group of following mass fraction：15 ~ 35 parts of natto powder, 5 ~ 8 parts of red yeast rice, 1 ~ 5 part of hawthorn, 3 ~ 10 parts of kudzu root extract, 3 ~ 10 parts of oligosaccharide；The oligosaccharide is the mixture of FOS and isomalto-oligosaccharide.The natto prescription that the present invention is provided; formula material is all medicine-food two-purpose material; edible safety, wide, preparation cost of originating are low; each component is reasonably combined by formula of the present invention, and with significant cooperative effect, promotion proliferation of intestinal probiotics is aid digestion, improve gastrointestinal function; the content of the cholesterol and triglycerides in serum can be also reduced simultaneously; dissolving vascular thrombosis, can comprehensive adjustment blood fat, protection are cardiovascular while intestinal microflora is nursed one's health, effect is notable.
Description
Technical field
The invention belongs to field of health care products, more particularly, to a kind of with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect
Natto prescription.
Background technology
With the improvement of people ' s living standards, to the health care demand of itself also stepping up, wherein, intestinal microecology system
The part united as normal bowel structure, the normal performance to function of intestinal canal is played a very important role.But due to existing
Changed by dietary structure for people, the accelerating of rhythm of life, psychology and social factor, broad-spectrum antibiotic use etc. it is many
Influence, such as phenomenon for occurring in that intestinal bacilli illness and making host cause a disease, acute and chronic diarrhea, constipation, IBS, inflammation
The disease of digestive systems such as property enteritis, and the metabolism related diseases such as Dyslipidemia, drastically influence the quality of life of people.
Wherein, the continuous expansion of people with hyperlipidemia causes the concern of researchers.High fat of blood refers to the concentration water of blood in human body in fat eliminating matter
Flat to be raised beyond normal range (NR), including serum total cholesterol TC levels, serum triglyceride TG levels are raised, serum high-density
The reduction of lipoprotein cholesterol HDL-C levels.Hyperlipemia, causes " blood is thick ", and in vascular wall deposition, serious formation thrombus is right
Human body it is very harmful, medical research shows, high fat of blood be the angiocardiopathies such as ischemic myocardial infarct, coronary heart disease and apoplexy most
Important pathogenesis, the elevated main cause of blood fat is caused by bad dietary factor, habits and customs and inherent cause etc..
Meanwhile, intestinal beneficial bacterium reduces the final synthesis for also resulting in cholesterol and absorbs increase, aggravates hyperlipemia.
Treatment high fat of blood is mainly by two kinds of approach of drug therapy and non-drug therapy, and it is easy that medicine adjusts the defect of fat
Drug dependence is produced, and long-term taking occurs the adverse reactions such as hepatorenal damage, rhabdomyolysis, stomachache, fash, and pair is made
With big, easily recurred after drug withdrawal.
Natto originates from China, is the bean product being made up of fermenting bacillus subtilis of soya bean, with stickiness, smell compared with
Smelly, taste is micro- sweet, not only possesses the nutritive value of soya bean, the digestibility rich in farnoquinone, raising protein, more important
Be that fermentation process generates several physiological active substances, with the guarantor for dissolving internal fibrin and other regulation physiological functions
Strong effect, can dissolve old bolt patch with bidirectional modulation blood pressure, adjust blood fat, and dispelling fatigue is comprehensive to improve body immunity.But
Be, there is presently no with natto as main component and collocation rationally, that activity composition high is applied to coordinating intestines and stomach reducing blood lipid is molten
The report of the field of health care products of thrombus.
The content of the invention
For above-mentioned weak point of the prior art, it is an object of the invention to provide one kind there is coordinating intestines and stomach to drop blood
The natto prescription of liposoluble thrombus effect, by medicine-food two-purpose food materials reasonable compatibility, with conditioning intestinal microflora, improves human body
Effect of immunity, reduction blood fat, softening blood vessel, thrombus and prevention cardiovascular and cerebrovascular disease.
Above-mentioned purpose of the invention is achieved by the following technical programs.
A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect, the natto prescription is by following mass fraction
Each group be grouped into：15 ~ 35 parts of natto powder, 5 ~ 8 parts of red yeast rice, 1 ~ 5 part of hawthorn, 3 ~ 10 parts of kudzu root extract, 3 ~ 10 parts of oligosaccharide；
The oligosaccharide is the mixture in FOS and isomalto-oligosaccharide.
Natto is the bean product being made up of fermenting bacillus subtilis of soya bean, wherein being disproportionated containing Nattokinase, oxide
Various function factors such as enzyme, catalase, protease, amylase, lipase and natto isoflavones, soap green grass or young crops element.Red yeast rice is with Xian
Rice is raw material, is formed through liquid deep layer fermenting using monascus ruber, and the main functional component in red yeast rice has monascorubin, Lip river to cut down him
The compounds such as the black alcohol of spit of fland class, ergot, enzymes activity material and GABA.Oligosaccharide is a small number of monose（2 ~ 10）Condensation
Polymer, the acquisition of oligosaccharide generally generally has following four：From natural material extraction, solid-state reaction under microwave method,
Acid-base chemical conversion method, enzyme hydrolysis method etc.；Oligosaccharide of the present invention refers to the mixture of FOS and isomalto-oligosaccharide.Hawthorn contains
There are vitamin C, lipase, various organic acids and flavone of hawthorn fruit.The root of kudzu vine is sweet, pungent, cool in nature, mainly contains Puerarin, daidzin
With the osajin active ingredient such as daidzein.Each component collocation is used according to prescription of the present invention, bioactivity is strong, and effect is complete
Face, edible safety realizes the organic combination of nutritional ingredient, effect, mechanism of action, and obtains and mutually promote between each composition
Enter, the effect of Synergistic, the natto prescription of reasonable compatibility is preferably adapted with the demand of human body, with significant conditioning intestines
Road microorganism species, comprehensive adjustment blood fat, the effect of thrombus.Also, when each component collocation of the natto prescription is used,
Each composition can be less than individually or the consumption that combines of main composition, comprehensive effect has been reached and surmounted and lifted each composition
The effect of exclusive use.
Preferably, the natto prescription is grouped into by each group of following mass fraction：25 ~ 30 parts of natto powder, red yeast rice 5 ~ 6
Part, 3 ~ 4 parts of hawthorn, 7 ~ 8 parts of kudzu root extract, 3 ~ 10 parts of oligosaccharide.
Preferably, the mass ratio of FOS and isomalto-oligosaccharide is 1 ~ 4 in the oligosaccharide:1.It is highly preferred that institute
The mass ratio for stating FOS and isomalto-oligosaccharide in oligosaccharide is 3:1.
Preferably, the natto powder includes Nattokinase.
Preferably, the kudzu root extract is the alcohol extract of kudzu-vine root powder.
Preferably, the red yeast rice includes Monacolin K.
Preferably, the hawthorn is the hawthorn powder of 50 ~ 60 mesh.
Natto powder, red yeast rice, hawthorn, kudzu root extract, FOS and isomalto-oligosaccharide in the present invention can be adopted
With existing preparation method or directly from commercially available.
Preferably, the natto powder is obtained in the following way：By raw material soybean with water soaked overnight；Then will soak
Soya bean pressure cooking 1h, it is uniform to spray into natto bacterium solution after the ripe beans after boiling are cooled to room temperature；Natto temperature control is existed
35 ~ 45 DEG C, relative humidity is 50 ~ 90%, and ferment 12 ~ 14h；The natto that will be fermented is placed in 4 DEG C of refrigerations, takes out, freeze-drying,
Crush, obtained final product after crossing 50 ~ 60 mesh sieves.
Preferably, the red yeast rice is obtained in the following way：Long-grained nonglutinous rice dipping is taken, water absorption is rinsed up to clear water after 20% and cooked,
Bent meal is obtained, the bent meal that will be cooked is stirred to dissipate and is cooled to 40 ~ 45 DEG C, inoculation, keeping temperature 24h at 40 ~ 45 DEG C again；The cultural hypha phase
After finishing, into the Pu head management phase, in 40 DEG C of ventilating fermentations, turn shakeouing, in 36 ~ 38 DEG C of temperature control cultures, Pu head stage
Turn 1 time, interval time is 5h, and keep humidity 65 ~ 75%, the red yeast rice that will be fermented after fermentation 28h dries below 55 DEG C
It is dry, obtained final product after crossing 50 ~ 60 mesh sieves.
Preferably, the kudzu root extract is obtained in the following way：The crushing of root of kudzu vine dry plate is taken, is 1 by solid-liquid ratio：6 add
Enter the ethanol solution of volume fraction 85%, in 1 ~ 3h of refluxing extraction at 70 DEG C, extract 2 ~ 3 times；Suction filtration, merging filtrate, subtract while hot
Pressure is concentrated to give without alcohol taste medicinal extract, as kudzu root extract.
Preferably, the prescription is also comprising acceptable auxiliary material.
Preferably, the natto prescription is in the one kind in lozenge, capsule, tablet, pulvis, ointment or spray.
Compared with prior art, beneficial effect of the present invention is：There is coordinating intestines and stomach reducing blood lipid the invention provides one kind
The natto prescription of effect, formula material is all medicine-food two-purpose material, and edible safety, wide, preparation cost of originating are low, and each component is pressed
Formula of the present invention is reasonably combined, and with significant cooperative effect, promotion proliferation of intestinal probiotics is aid digestion, improve intestines and stomach
Function, while can also reduce the content of the cholesterol and triglycerides in serum, dissolves vascular thrombosis, can be micro- in conditioning enteron aisle
Comprehensive adjustment blood fat, protection are cardiovascular while biological flora, and effect is notable.
Specific embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.Unless stated otherwise, the reagent for using of the invention, method and apparatus are the art conventional reagent, method
And equipment.
Natto is a kind of time-honored functional health food of the soybean through fermenting bacillus natto.The protein of soybean
With indissolubility, but after being made as natto, become solvable, and produce amino acid, non-existent various ferment in raw material, due to
Bacillus natto and the generation of association probiotics, can help gastrointestinal disturbances to absorb.Bean product after fermentation, the utilization rate of protein is carried
It is high.In natto containing Nattokinase, superoxide dismutase, catalase, protease, amylase, lipase and natto isoflavones,
Soap green grass or young crops various function factors such as element, can effectively reduction blood fat, cholesterol and peroxidating matter pigment in removing brain tissue cell.Natto
In mucoitin have the effect similar to dietary fiber, it can reduce human body to fat absorption.Natto is rich in various nutrition
Element, can dissolve outmoded thrombus patch with the intestines problem such as Constipation, diarrhoea with bidirectional modulation blood pressure, adjust blood fat, comprehensive
Close and improve body immunity.
Red yeast rice be it is a kind of it is pure natural, safe, be beneficial to the food additives of health.By body metabolism approach
Research show that human body itself synthetic cholesterol need to be by a series of metabolic processes, and to defend two acyls auxiliary wherein key is exactly methylol
Enzyme A（HMG-CoA）In its reductase（HMG-CoA-R）In the presence of generate mevalonic acid, further synthetic cholesterol.And it is red
The competitive inhibitor of effective ingredient exactly HMG-CoA reductase in song（Monacolin K）, so as to just block synthetic cholesterol
Path, play a part for the treatment of with prevention cardiovascular and cerebrovascular disease.Additionally, Monacolin K can also increase the decomposition generation of cholesterol
Thank.The synthesis of cholesterol can be suppressed due to Monacolin K, so as to reduce the concentration of cholesterol in liver cell, and liver cell
Middle cholesterol concentration reduces again that low-density lipoprotein ldl receptor increases in cell cultured supernatant, makes organism from body-internal-circulation
In dispose LDL and LDL precursors, while the synthesis of apoprotein apo B-100 in LDL and LDL can also be suppressed, so as to drop
The synthesis and secretion of the materials such as low TG, lipoprotein.
Hawthorn is stone fruit, it is drying after can be used as medicine, be Chinese distinctive medicine fruit dual-purpose seeds, with reducing blood lipid, blood
Pressure, cardiac stimulant, arrhythmia etc. are acted on, while being also the good medicine of spleen benefiting and stimulating the appetite, relieving dyspepsia, phlegm reduction of blood circulation promoting.Hawthorn is to stomach and intestine
Motor function has adjustment effect, and hawthorn contains various organic acids, and oral rear enhancing gastric acidity improves pepsin activity, promotees
Enter the digestion of protein；Contain lipase in hawthorn, flavone of hawthorn fruit can promote the digestion of fat, increase the secretion of gastric juice；
Hawthorn is sour, stimulates stomach lining to promote gastric secretion, whets the appetite.Additionally, hawthorn can be by suppressing the conjunction of hepatic cholesterol
Into effect for reducing blood fat is carried out, with reduction serum total cholesterol（TC）, LDL-C and apolipoprotein B（ApoB）
Concentration, increasing high density lipoprotein-cholesterol（HDL-C）And aPoA（ApoA）Concentration, but to triglycerides（TG）Shadow
Ring little.
The root of kudzu vine first recorded in《Sheng Nong's herbal classic》, it is the dry root of legume pueraria lobata, brought down a fever with expelling pathogenic factors from muscles and skin, promoted the production of body fluid to quench thirst,
Treating measles, the function of Shengyang Zhixie, are the plant of medicine-food two-purpose in China.Kudzu root extract rich in the root of kudzu vine primary efficacy into
Point, the osajin active ingredient such as Puerarin, daidzin and daidzein is specifically contained, root of kudzu vine total isoflavone has increase coronal
Blood flow volume, stimulate circulation, strengthen various pharmacology such as immunity of organisms and reduce myocardial oxygen consumption and health-care effect.
Oligosaccharide, also known as oligosaccharides, is a small number of monose（2 ~ 10）The polymer of condensation, can be obtained by polysaccharide hydrolysis, also may be used
Pass through：Extraction, solid-state reaction under microwave method, acid-base chemical conversion method, enzyme hydrolysis method etc. are obtained from natural material.Oligosaccharide has many
Kind, their common feature is：It is difficult to be absorbed by gastro-intestinal digestion, sugariness is low, and heat is low, does not increase blood sugar and blood fat substantially.It is low
The following healthcare function of glycan：Improve micro-ecological environment in human body, be conducive to the propagation of Bifidobacterium and other beneficial bacteriums, through metabolism
Producing organic acid reduces intestinal pH, suppresses the growth of enteral salmonella and spoilage organisms, adjusts gastrointestinal function, suppresses enteral
Corrupt substance, it is anti-to treat constipation, and increase vitamin synthesis, improve immune function of human body.The common oligosaccharide of in the market has oligomeric
Isomaltose, FOS, galactooligosaccharide, xylo-oligosaccharide, lactosucrose, soyabean oligosaccharides, inulin etc..
Natto powder, red yeast rice, hawthorn, kudzu root extract, FOS and isomalto-oligosaccharide in specific embodiment are
Existing preparation method is prepared or directly from commercially available, and wherein hawthorn, FOS and isomalto-oligosaccharide are commercially available
Buy, natto powder, red yeast rice, kudzu root extract are adopted and prepared with the following method.
The natto powder is obtained in the following way：By raw material soybean with water soaked overnight；Then by soaked soya bean
Pressure cooking 1h, it is uniform to spray into natto bacterium solution after the ripe beans after boiling are cooled to room temperature；By natto temperature control at 40 DEG C,
Relative humidity is 50 ~ 90%, and ferment 14h；The natto that will be fermented is placed in 4 DEG C of refrigerations, takes out, freeze-drying, crushes, and crosses 50 ~ 60
Obtained final product after mesh sieve.The natto powder includes Nattokinase.
The red yeast rice is obtained in the following way：Long-grained nonglutinous rice dipping is taken, water absorption is rinsed up to clear water after 20% and cooked, and obtains song
Meal, the bent meal that will be cooked is stirred to dissipate and is cooled to 40 DEG C, inoculation, keeping temperature 24h at 42 DEG C again；After the cultural hypha phase finishes, enter
The Pu head management phase, in 40 DEG C of ventilating fermentations, turn shakeouing, in 36 ~ 38 DEG C of temperature control cultures, the Pu head stage turns 1 time, is spaced
Time is 5h, and keeps humidity 65 ~ 75%, and the red yeast rice that will be fermented after fermentation 28h is dried below 55 DEG C, crosses 50 ~ 60 mesh sieves
After obtain final product.The red yeast rice includes Monacolin K.
The kudzu root extract is obtained in the following way：The crushing of root of kudzu vine dry plate is taken, is 1 by solid-liquid ratio：6 add volume integral
The ethanol solution of number 85%, in 1 ~ 3h of refluxing extraction at 70 DEG C, extracts 2 ~ 3 times；Suction filtration, merging filtrate, are concentrated under reduced pressure while hot
To without alcohol taste medicinal extract, as kudzu root extract.
It is standby after each raw material 50 ~ 60 mesh sieves excessively, then it is prepared by mixing into natto prescription of the present invention.
On the basis of natto prescription is prepared into, the acceptable auxiliary material of addition by natto prescription of the present invention be made lozenge, capsule,
Tablet, pulvis, ointment or spray are little to its potency due.
Embodiment 1
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function, the natto prescription is grouped by each group of following mass fraction
Into：28 parts of natto powder, 5 parts of red yeast rice, 3 parts of hawthorn, 7.5 parts of kudzu root extract, 3 parts of oligosaccharide；FOS in the oligosaccharide
It is 3 with the mass ratio of isomalto-oligosaccharide:1.
Embodiment 2
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function, the natto prescription is grouped by each group of following mass fraction
Into：25 parts of natto powder, 6 parts of red yeast rice, 4 parts of hawthorn, 7 parts of kudzu root extract, 10 parts of oligosaccharide；The composition of the oligosaccharide and implementation
Example 1 is identical.
Embodiment 3
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function, the natto prescription is grouped by each group of following mass fraction
Into：30 parts of natto powder, 6 parts of red yeast rice, 3 parts of hawthorn, 8 parts of kudzu root extract, 6 parts of oligosaccharide；The composition of the oligosaccharide and implementation
Example 1 is identical.
Embodiment 4
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function, the natto prescription is grouped by each group of following mass fraction
Into：35 parts of natto powder, 6.5 parts of red yeast rice, 1 part of hawthorn, 10 parts of kudzu root extract, 6 parts of oligosaccharide；The composition and reality of the oligosaccharide
Apply example 1 identical.
Embodiment 5
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function, the natto prescription is grouped by each group of following mass fraction
Into：15 parts of natto powder, 8 parts of red yeast rice, 5 parts of hawthorn, 3 parts of kudzu root extract, 10 parts of oligosaccharide；The composition of the oligosaccharide and implementation
Example 1 is identical.
Embodiment 6
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function, the natto prescription is grouped by each group of following mass fraction
Into：24 parts of natto powder, 5 parts of red yeast rice, 2.5 parts of hawthorn, 8.5 parts of kudzu root extract, 3 parts of oligosaccharide；The composition of the oligosaccharide with
Embodiment 1 is identical.
Embodiment 7
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function, the natto prescription is grouped by each group of following mass fraction
Into：30 parts of natto powder, 7 parts of red yeast rice, 4.5 parts of hawthorn, 6.5 parts of kudzu root extract, 8 parts of oligosaccharide；The composition of the oligosaccharide with
Embodiment 1 is identical.
Embodiment 8
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function of the present embodiment is substantially the same with embodiment 1, and difference exists
In the mass ratio of FOS and isomalto-oligosaccharide is 1 in the oligosaccharide:1.
Embodiment 9
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function of the present embodiment is substantially the same with embodiment 1, and difference exists
In the mass ratio of FOS and isomalto-oligosaccharide is 2 in the oligosaccharide:1.
Embodiment 10
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function of the present embodiment is substantially the same with embodiment 1, and difference exists
In the mass ratio of FOS and isomalto-oligosaccharide is 4 in the oligosaccharide:1.
Comparative example 1
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function of this comparative example is substantially the same with embodiment 1, and difference exists
In the natto powder and the red yeast rice are 16.5 parts.
Comparative example 2
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function of this comparative example, is grouped into by each group of following mass fraction：
28 parts of natto powder, 5 parts of red yeast rice, 10 parts of hawthorn, 1.5 parts of kudzu root extract, 2 parts of oligosaccharide；In the oligosaccharide FOS and
The mass ratio of isomalto-oligosaccharide is 3:1.
Comparative example 3
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function of this comparative example is substantially the same with embodiment 1, and difference exists
In the mass ratio of FOS and isomalto-oligosaccharide is 5 in the oligosaccharide:1.
Comparative example 4
A kind of natto prescription with coordinating intestines and stomach blood fat reducing function of this comparative example is substantially the same with embodiment 1, and difference exists
In the FOS is replaced with into galactooligosaccharide.
Application examples 1
Blood fat reducing function to embodiment 1 ~ 10 and the natto prescription of comparative example 1 ~ 4 is detected.
1）, test material：The natto prescription that embodiment 1 ~ 10 and comparative example 1 ~ 4 are prepared by the same way.
2）, subjects：Male Waster rats are randomly selected, the age is 6 week old or so.
3）, test method：After the male Waster rats chosen normally are raised into 7 days with basal feed, rat-tail blood is taken, examined
The blood fat of rat is surveyed, by TC levels, animal control group, hyperlipidemia model group, experiment A/B/C/D/E/F/G/H/M/N is randomly divided into
（The natto prescription of correspondence embodiment 1 ~ 10）, positive controls one/bis-/tri-/tetra-（The natto prescription of correspondence comparative example 1 ~ 4）, remove
Outside control group fed basal feed, remaining rat feeding high lipid food（High lipid food：Basal feed 78.8%, lard 10%, courage is solid
Alcohol 1%, yolk powder 10%, cholate 0.2%）, each group dose is as follows：
Control group：The isometric physiological saline of gavage；Hyperlipidemia model group：The isometric physiological saline of gavage；Experiment A/B/C/D/
E/F/G/H/M/N groups, positive controls one/bis-/tri-/tetra-, the embodiment 1 ~ 10 and comparative example 1 ~ 4 of difference gavage 2.5g/kg are made
The standby natto prescription（Previous experiments have verified that effective with 2.5g/kg concentration gavages）；
Successive administration 30 days, forbids rats eating and weighs after 30 days, fasting second day, takes rat-tail blood drawing, and rat is detected respectively
The TC of serum（T-CHOL）、TG（Triglycerides）.Variance analysis statistics is carried out to experimental data with SPSS softwares, above-mentioned
In three indexs, if the TC of serum（T-CHOL）、TG（Triglycerides）The two indexs are the positive, you can judge test sample
The hypolipemic function zoopery of product is the positive.
4）, result of the test：
Result of the test is as shown in table 1 ~ 3.
Body weight situation of change before and after each group rat test of table 1（X±S）
* there were significant differences with hyperlipidemia model group（P ＜ 0.05）
Shown by table 1, with the increase of feeding time, all experimental animal body weight all rise, wherein, experiment A ~ C groups are relative to be increased
Weight is less.Each group growth of animal, activity are normal, and the weight of animals of hyperlipidemia model group compares that there were significant differences with control group（P ＜
0.05）, experiment A/B/C/D/E/F/G/H/M/N groups, the body weight of the animal of positive controls one/bis-/tri-/tetra- compares with control group has
Growth trend, but without difference（P ＞ 0.05）.
TG situations of change before and after each group rat test of table 2
Compared with hyperlipidemia model group, * P ＜ 0.05.
As shown in Table 2, before giving high lipid food, each group rat blood serum triglycerides TG contents are more balanced, each group difference
It is not notable（P ＞ 0.05）.To the 30th day, the TG contents of hyperlipidemia model group（1.785±0.373 mmol·L-1）Higher than control group
（1.188±0.281 mmol·L-1）, and difference has conspicuousness（P ＜ 0.05）, point out fat animal model high to set up.It is tested to
30th day, experiment A/B/C/D/E/F/G/H/M/N groups, the TG contents of the rat of positive controls one/bis-/tri-/tetra- were below fat high
Model group, and experiment A/B/C/D/E/F/G/H/M/N groups have conspicuousness with the difference of hyperlipidemia model group（P ＜ 0.05）, display
The natto prescription of embodiment 1 ~ 10 has the effect of the serum triglyceride TG contents for reducing feeding high lipid food rat.Also,
The effect of experiment A ~ C group regulation TG contents is more significantly, illustrates that preferred prescription of the invention is：25 ~ 30 parts of natto powder, red yeast rice 5 ~
6 parts, 3 ~ 4 parts of hawthorn, 7 ~ 8 parts of kudzu root extract, 3 ~ 10 parts of oligosaccharide.Control group one changes natto powder and the relative of red yeast rice contains
Amount, control group two changes the relative amount of hawthorn, kudzu root extract and oligosaccharide, and control group three/tetra- changes oligosaccharide respectively
Content and composition, the effect that it reduces TG contents not as good as natto prescription of the present invention, illustrate natto prescription of the present invention composition and
Relative amount needs just to can reach the effect of described Synergistic in the range of restriction.
TC situations of change before and after each group rat test of table 3
Compared with hyperlipidemia model group, * P ＜ 0.05.
As shown in Table 3, no significant difference of the serum total cholesterol TC contents of each group rat between each group before experiment（P
＞ 0.05）.To the 30th day, the TC contents of hyperlipidemia model group（2.608±0.378 mmol·L-1）Higher than control group（2.021±
0.355 mmol·L-1）, and difference has conspicuousness（P ＜ 0.05）, point out fat animal model high to set up.It is tested to the 30th day,
Experiment A/B/C/D/E/F/G/H/M/N groups, the TC contents of the rat of positive controls one/bis-/tri-/tetra- are below hyperlipidemia model group,
And experiment A/B/C/D/E/F/G/H/M/N groups have conspicuousness with the difference of hyperlipidemia model group（P ＜ 0.05）, display embodiment 1 ~
10 natto prescription has the effect of the serum total cholesterol TC contents for reducing feeding high lipid food rat.Also, experiment A ~ C groups
The effect for adjusting TC contents is more significantly, illustrates that preferred prescription of the invention is：25 ~ 30 parts of natto powder, 5 ~ 6 parts of red yeast rice, hawthorn 3
~ 4 parts, 7 ~ 8 parts of kudzu root extract, 3 ~ 10 parts of oligosaccharide.Control group one changes the relative amount of natto powder and red yeast rice, control group two
Change the relative amount of hawthorn, kudzu root extract and oligosaccharide, control group three/tetra- changes the content and composition of oligosaccharide respectively,
The effect that it reduces TC contents not as good as natto prescription of the present invention, illustrates the composition and relative amount needs of natto prescription of the present invention
The effect of described Synergistic is just can reach in the range of restriction.
Application examples 2
Thrombus dissolving effect to embodiment 1 ~ 10 and the natto prescription of comparative example 1 ~ 4 is detected.
1）, test material：The natto prescription that embodiment 1 ~ 10 and comparative example 1 ~ 4 are prepared by the same way.
2）, subjects：Randomly select large ear rabbit, male and female half and half, 2.0 ± 0.2kg of body weight.
3）, test method：By the large ear rabbit of selection before administration by arteria carotis communis separation is only carried out, dissociate about 2cm
Proximal part long and distal end, are clamped with parteriole, allow blood to pass through in intravascular, after 1.5h, thrombosis in arteria carotis, examination
A/B/C/D/E/F/G/H/M/N groups be tested respectively to the natto prescription of large ear rabbit gavage 2g/kg embodiments 1 ~ 10, positive controls
The natto prescription of one/bis-/tri-/tetra- difference gavage 2g/kg comparative examples 1 ~ 4（Previous experiments are had verified that with 2g/kg concentration gavages to be had
Effect）, the isometric physiological saline of blank control group gavage puts to death large ear rabbit, cuts carotid artery vascular after 5 hours, cuts blood vessel open
Silk thread and thrombus are taken out, it is long to measure 1cm, claims its weight, thrombus is then put in 60 DEG C of drying in baking oven, calculate carotid thrombosis
Weight in wet base and dry weight, and compare with physiological saline, check for significant difference, the results are shown in Table 4.
4）, result of the test：Result of the test is as shown in table 4.
The influence of the embodiment 1 ~ 10 of table 4 and the natto prescription of comparative example 1 ~ 4 to large ear rabbit thrombolysis
Note：Compared with blank control group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001.
As shown in Table 4, the natto for being prepared to the large ear rabbit gavage embodiment of the present invention 1 ~ 10 for forming carotid thrombus
After prescription, either the weight in wet base or dry weight of thrombus, as a result show that thrombus has obvious thrombolytic effect, and will become apparent from examination
Test A/B/C/G groups（Embodiment 1,2,3,7）The effect of thrombus dissolving is more protruded.Control group one changes the relative of natto powder and red yeast rice
Content, control group two changes the relative amount of hawthorn, kudzu root extract and oligosaccharide, and control group three/tetra- changes oligosaccharide respectively
Content and composition, though its natto prescription also has certain thrombus dissolving effect, substantially be not so good as prescription of the present invention, illustrate warp largely
The collocation of the natto prescription of the present invention that early-stage Study optimization is obtained rationally, has reached Synergistic in the case of proportion optimizing
Effect.
Application examples 3
The natto prescription for choosing embodiment 1,8,9,10 and comparative example 1 ~ 4 is detected to effect of coordinating intestines and stomach of the present invention.
Randomly select 480 clinical symptoms and be related to the volunteer of indigestion, constipation, lassitude hypodynamia, men and women half and half, the age
35 ± 6 years old.Eight groups are randomly divided into, respectively the natto prescription tablet of oral embodiment 1,8,9,10 and comparative example 1 ~ 4,6 ~ 9g/ days,
Orally, 14 days.Normal diet during the oral natto prescription tablet, uses without other sour milk beverages.
The coordinating intestines and stomach clinical test results of table 5
As shown in Table 5, effective number of cases of embodiment 1 reaches 50, total effective rate 83.3%, and the total effective rate of comparative example 1 ~ 4≤
65%, illustrate to change the relative amount of natto powder and red yeast rice, or change the relative amount of hawthorn, kudzu root extract and oligosaccharide, or
Change the content and composition of oligosaccharide, will all directly affect the effect of coordinating intestines and stomach of the present invention, and the natto group that the present invention is limited
Effect of the side with good coordinating intestines and stomach, a kind of coordinating intestines and stomach reducing blood lipid thrombus dissolving of determined curative effect is provided for many patients
Health products.
Summary result of the test, natto prescription compatibility of the invention is reasonable, effect notable, has collaboration between each prescription
The effect of synergy, it is necessary to coordinating intestines and stomach of the present invention and reducing blood lipid effect are just can reach in the range of the restriction of prescription of the present invention
Really；Certain component in the present invention is such as substituted for other conventional constituents（Comparative example 4）, or change one or more groups in prescription
The content divided（Comparative example 1 ~ 3）Although can also there is certain effect, effect is significantly worse than the present invention.Therefore, it is of the invention to receive
Beans prescription is creative.
Claims (10)
1. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect, it is characterised in that the natto prescription by with
The each group of lower mass fraction is grouped into：15 ~ 35 parts of natto powder, 5 ~ 8 parts of red yeast rice, 1 ~ 5 part of hawthorn, 3 ~ 10 parts of kudzu root extract is low
3 ~ 10 parts of glycan；The oligosaccharide is the mixture of FOS and isomalto-oligosaccharide.
2. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 1, its feature exists
In the natto prescription is grouped into by each group of following mass fraction：25 ~ 30 parts of natto powder, 5 ~ 6 parts of red yeast rice, 3 ~ 4 parts of hawthorn,
7 ~ 8 parts of kudzu root extract, 3 ~ 10 parts of oligosaccharide.
3. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 1 and 2, its feature
It is that the mass ratio of FOS and isomalto-oligosaccharide is 1 ~ 4 in the oligosaccharide:1.
4. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 3, its feature exists
In the mass ratio of FOS and isomalto-oligosaccharide is 3 in the oligosaccharide:1.
5. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 1, its feature exists
In the natto powder includes Nattokinase.
6. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 1, its feature exists
In the kudzu root extract is the alcohol extract of kudzu-vine root powder.
7. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 1, its feature exists
In the red yeast rice includes Monacolin K.
8. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 1, its feature exists
In the hawthorn is the hawthorn powder of 50 ~ 60 mesh.
9. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 1, its feature exists
In the prescription is also comprising acceptable auxiliary material.
10. a kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect according to claim 1, its feature exists
In the natto prescription is in the one kind in lozenge, capsule, tablet, pulvis, ointment or spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710042376.2A CN106798252B (en) | 2017-01-20 | 2017-01-20 | Natto product with effects of regulating intestines and stomach, reducing blood fat and dissolving thrombus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710042376.2A CN106798252B (en) | 2017-01-20 | 2017-01-20 | Natto product with effects of regulating intestines and stomach, reducing blood fat and dissolving thrombus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106798252A true CN106798252A (en) | 2017-06-06 |
| CN106798252B CN106798252B (en) | 2020-08-18 |
Family
ID=58986821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710042376.2A Active CN106798252B (en) | 2017-01-20 | 2017-01-20 | Natto product with effects of regulating intestines and stomach, reducing blood fat and dissolving thrombus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106798252B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109645464A (en) * | 2019-01-10 | 2019-04-19 | 蕴彤本草(北京)生物科技有限公司 | With blood activating and fat reducing thrombolysis and stroke rehabilitation effect composite nutrient and preparation method |
| CN109700006A (en) * | 2018-12-13 | 2019-05-03 | 深圳市淳睿贸易有限公司 | Natto enzyme composition |
| CN110613089A (en) * | 2019-05-05 | 2019-12-27 | 宁波御坊堂生物科技有限公司 | Composition with functions of reducing blood fat and improving gastrointestinal tract and preparation method thereof |
| CN110859869A (en) * | 2019-12-20 | 2020-03-06 | 中国中医科学院中医药科技合作中心 | A composition for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
| CN111000218A (en) * | 2019-11-14 | 2020-04-14 | 北京一品堂医药科技有限公司 | Formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis |
| CN111480758A (en) * | 2019-01-29 | 2020-08-04 | 金振库 | Natto and pollen typhae solid beverage and preparation method thereof |
| CN111528386A (en) * | 2020-06-11 | 2020-08-14 | 陕西开元制药有限公司 | Hawthorn and natto solid beverage and preparation method thereof |
| CN114680338A (en) * | 2022-04-23 | 2022-07-01 | 安徽燕婉健康科技有限公司 | Probiotic composition with effects of dissolving thrombus, reducing blood fat and regulating intestinal flora and preparation method thereof |
| CN114868927A (en) * | 2022-05-31 | 2022-08-09 | 黄河三角洲京博化工研究院有限公司 | Compound hypolipidemic capsule and preparation method thereof |
| CN117204565A (en) * | 2023-09-13 | 2023-12-12 | 深圳康普生物药业有限公司 | Medicinal and edible composition for reducing blood fat and blood pressure and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105249451A (en) * | 2015-10-09 | 2016-01-20 | 广州市炜鑫生物科技有限公司 | Nourishment containing natto and red yeast rice and preparation method thereof |
| CN105310075A (en) * | 2015-09-23 | 2016-02-10 | 威海南波湾生物技术有限公司 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
| CN106072527A (en) * | 2016-06-16 | 2016-11-09 | 武汉虹辰远荣生物制品有限公司 | A kind of natto prescription of eliminating toxin and beautifying the skin and preparation method thereof |
-
2017
- 2017-01-20 CN CN201710042376.2A patent/CN106798252B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105310075A (en) * | 2015-09-23 | 2016-02-10 | 威海南波湾生物技术有限公司 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
| CN105249451A (en) * | 2015-10-09 | 2016-01-20 | 广州市炜鑫生物科技有限公司 | Nourishment containing natto and red yeast rice and preparation method thereof |
| CN106072527A (en) * | 2016-06-16 | 2016-11-09 | 武汉虹辰远荣生物制品有限公司 | A kind of natto prescription of eliminating toxin and beautifying the skin and preparation method thereof |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109700006A (en) * | 2018-12-13 | 2019-05-03 | 深圳市淳睿贸易有限公司 | Natto enzyme composition |
| CN109645464A (en) * | 2019-01-10 | 2019-04-19 | 蕴彤本草(北京)生物科技有限公司 | With blood activating and fat reducing thrombolysis and stroke rehabilitation effect composite nutrient and preparation method |
| CN111480758A (en) * | 2019-01-29 | 2020-08-04 | 金振库 | Natto and pollen typhae solid beverage and preparation method thereof |
| CN110613089A (en) * | 2019-05-05 | 2019-12-27 | 宁波御坊堂生物科技有限公司 | Composition with functions of reducing blood fat and improving gastrointestinal tract and preparation method thereof |
| CN111000218A (en) * | 2019-11-14 | 2020-04-14 | 北京一品堂医药科技有限公司 | Formula product capable of adjusting intestines and stomach and preventing cerebral thrombosis |
| CN110859869A (en) * | 2019-12-20 | 2020-03-06 | 中国中医科学院中医药科技合作中心 | A composition for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
| CN111528386A (en) * | 2020-06-11 | 2020-08-14 | 陕西开元制药有限公司 | Hawthorn and natto solid beverage and preparation method thereof |
| CN111528386B (en) * | 2020-06-11 | 2022-07-29 | 陕西开元制药有限公司 | Hawthorn and natto solid beverage and preparation method thereof |
| CN114680338A (en) * | 2022-04-23 | 2022-07-01 | 安徽燕婉健康科技有限公司 | Probiotic composition with effects of dissolving thrombus, reducing blood fat and regulating intestinal flora and preparation method thereof |
| CN114868927A (en) * | 2022-05-31 | 2022-08-09 | 黄河三角洲京博化工研究院有限公司 | Compound hypolipidemic capsule and preparation method thereof |
| CN117204565A (en) * | 2023-09-13 | 2023-12-12 | 深圳康普生物药业有限公司 | Medicinal and edible composition for reducing blood fat and blood pressure and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106798252B (en) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106798252A (en) | A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect | |
| CN101347193B (en) | Compound rice capable of providing balanced nutrition and preparing art thereof | |
| CN101695354B (en) | Predigested soyfood | |
| CN105192832A (en) | Composition of probiotic fermented horseradish tree leaves as well as preparation method and application of composition | |
| CN103766904A (en) | Preparation of capsule with function of lowering lipid and facilitating feces excretion and application of capsule | |
| CN110771825A (en) | Comprehensive nutrition powder for reducing fat, blood sugar, blood pressure and blood fat and preparation method thereof | |
| CN109966426A (en) | A kind of Chinese medicine immunomodulator of jujube Radix Astragali mixed fermentation and preparation method thereof | |
| CN110973423A (en) | Red yeast noni beverage and preparation method thereof | |
| CN111329055B (en) | Preparation method of trifoliate acanthopanax enzyme | |
| CN102177993B (en) | Stomach-strengthening and digestion-promoting tea and preparation method thereof | |
| CN101496568A (en) | Mung bean or pea dietary fiber and method for producing the same | |
| JP2006238730A (en) | Liver function-enhancing health food | |
| CN107212392A (en) | A kind of full nutrition fermentation health-preserving food and preparation method thereof | |
| CN115053929B (en) | Formula milk powder suitable for fatty liver people and preparation thereof | |
| KR20110118911A (en) | Lactic acid bacteria fermented extract using cereals and herb medicine materials, and method of preparing thereof | |
| CN109620903A (en) | A kind of health instant powder with improvement intestinal absorption ability | |
| CN109497470A (en) | A kind of chlorella pyrenoidosa polypeptide alleviates getting fat composition and preparation method thereof | |
| CN115777933A (en) | Composition for regulating metabolism, reducing fat and controlling sugar and application thereof | |
| JP2006006156A (en) | Liver function-enhancing health food | |
| CN107536061A (en) | Compound probiotic dietary fiber with and preparation method thereof | |
| CN111938147A (en) | Mulberry ganoderma lactobacillus co-fermentation product and preparation method and application of extract thereof | |
| CN111357902A (en) | Functional beverage capable of reducing blood fat and preparation method thereof | |
| CN111436618A (en) | Passion fruit polypeptide composition and preparation method thereof | |
| CN111184203A (en) | Japanese soy sauce with blood lipid reducing effect and its brewing method | |
| CN110623266A (en) | Health food for assisting in reducing blood sugar and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |